Literature DB >> 16048570

Factors affecting the mortality of pediatric fulminant hepatic failure in relation to hepatitis B virus infection.

Pei-Chun Chan1, Huey-Ling Chen, Man-Shan Kong, Fu-Chen Huang, Hung-Chang Lee, Chieh-Chung Lin, Ching-Chuan Liu, I-Hsien Lee, Tzee-Chung Wu, Shu-Fen Wu, Yen-Hsuan Ni, Hong-Yuan Hsu, Mei-Hwei Chang.   

Abstract

AIM: To investigate the factors affecting the outcome of fulminant hepatic failure (FHF) in children in relation to hepatitis B virus (HBV) infection.
METHODS: Retrospective review of a total of 94 cases (61 males and 33 females, aged from 1 month to 15 years) recruited from nine tertiary referral centers in Taiwan from 1985 to 1999.
RESULTS: The overall mortality rate was 75%. Patients in the mortality group were of an older age, had higher peak total bilirubin levels, a longer prothrombin time, and a lower percentage of HBV positivity (P < 0.001, P = 0.003, P = 0.0027 and P = 0.042, respectively). Mortality was 65% in the HBV positive (n = 42) and 83% in the HBV negative (n = 52) group (P = 0.05). In the HBV positive group, the prothrombin time was noted to be the single factor affecting outcome (P = 0.036). In the HBV negative group, older age and higher peak value of total serum bilirubin were suggestive of poor survival rate (P < 0.001 and P = 0.006, respectively). Multivariate analysis revealed that total bilirubin was the single factor affecting outcome in the HBV-negative group. The mortality rate of HBV positive children in three consecutive time periods without liver transplantation (1985-1989, 1990-1994, 1995-1999) decreased gradually (91, 67 and 38%, respectively, with P = 0.027). This change was not observed in HBV-negative cases.
CONCLUSIONS: Hepatitis B virus positive FHF had a lower mortality rate than HBV negative FHF, with each group having different factors affecting mortality.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16048570     DOI: 10.1111/j.1440-1746.2005.03923.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  3 in total

1.  Nucleoside analogues improve the short-term and long-term prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure.

Authors:  Tianyan Chen; Yingli He; Xiaojing Liu; Zhi Yan; Ke Wang; Hongli Liu; Shuling Zhang; Yingren Zhao
Journal:  Clin Exp Med       Date:  2011-10-15       Impact factor: 3.984

2.  Initial load of hepatitis B virus (HBV), its changing profile, and precore/core promoter mutations correlate with the severity and outcome of acute HBV infection.

Authors:  Shigehiko Sainokami; Koichi Abe; Akihiro Sato; Ryujin Endo; Yasuhiro Takikawa; Kazuyuki Suzuki; Hiroaki Okamoto
Journal:  J Gastroenterol       Date:  2007-03-30       Impact factor: 7.527

3.  Economic evaluation of delivering hepatitis B vaccine to injection drug users.

Authors:  Yiqing Hu; Lauretta E Grau; Greg Scott; Karen H Seal; Patricia A Marshall; Merrill Singer; Robert Heimer
Journal:  Am J Prev Med       Date:  2008-07       Impact factor: 5.043

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.